Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
FORM 4
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Thermo Fisher Scientific is a life sciences and laboratory equipment company supplying instruments, reagents, consumables, and services to pharmaceutical, biotech, academic, and industrial customers worldwide.
Business model
The company earns revenue from a mix of equipment sales and highly recurring consumables and services revenue tied to ongoing lab operations, which provides steadier demand than a pure equipment sales model.
Growth drivers
- Growth in biopharma research and manufacturing outsourcing
- Recovery in academic and government research funding
- Expansion of bioproduction services for biologic drug manufacturers
- Continued consumables demand from its large installed instrument base
Competitive position
Thermo Fisher's broad product portfolio and scale let it serve nearly every stage of the life sciences research and manufacturing process, giving it a uniquely comprehensive position relative to more specialized competitors.
Risks
Research funding cycles, particularly academic and government spending, can create demand volatility, and reduced biopharma research spending during industry downturns can weigh on its consumables and equipment sales.
Valuation
Thermo Fisher typically trades at a premium multiple reflecting its recurring revenue mix and broad market position, with sentiment closely tied to biopharma and academic research spending trends.
Final view
Overall rating: 74/100
Thermo Fisher's broad exposure across the life sciences research and manufacturing value chain makes it a core holding for exposure to biotech tools. My view is favorable, with research funding cycles as the main swing factor for near term growth.
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.